Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2024-09-23
Original market date: See footnote 1
2019-11-20
Product name:
BAQSIMI
Description:
SINGLE-DOSE DEVICE
DIN:
02492415
Product Monograph/Veterinary Labelling:
Date:
2024-02-14
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
AMPHASTAR PHARMACEUTICALS, INC.
11570 Sixth Street
Rancho Cucamonga
California
United States
91730
Class:
Human
Dosage form(s):
Powder
Route(s) of administration:
Nasal
Number of active ingredient(s):
1
Schedule(s):
Ethical
American Hospital Formulary Service (AHFS): See footnote 3
68:22.12
Anatomical Therapeutic Chemical (ATC): See footnote 4
H04AA01 GLUCAGON
Active ingredient group (AIG) number:See footnote5
0101772002
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| GLUCAGON | 3 MG / CONTAINER |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.